IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...

With autoimmune pancreatitis linked to a higher cancer risk, doctors must use comprehensive imaging to avoid unnecessary ...

In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased ...

New diagnostic criteria are enhancing accuracy in identifying IgG4-related periaortitis, periarteritis, and retroperitoneal ...

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment for the rare and recently recognized autoimmune condition, according to ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

About Immunoglobulin G4-related disease (IgG4-RD) UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease ...

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a chronic and debilitating immune-mediated inflammatory ...